Phaseline

Targets › NAGLU

NAGLU (Alpha-N-acetylglucosaminidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2029.

Involved in the degradation of heparan sulfate. (UniProt, P54802)

Open in Phaseline: the race on NAGLU, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
JCR PharmaceuticalsJR-441 (posnafusp alfa)
Recombinant N-acetyl-alpha-glucosaminidase (NAGLU) enzyme replacement therapy
NAGLUPhase 1Mucopolysaccharidosis III-AOct 2029

Conditions

Mucopolysaccharidosis III-A (1)

Modalities

small molecule (1)

Companies

JCR Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.